Immunitybio

Yahoo Finance • 20 hours ago

Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Wednesday; ImmunityBio to Advance, Novo Nordisk to Decline

The most-talked-about stocks in the Reddit subforum Wallstreetbets were mostly advancing hours befor PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 21 hours ago

ImmunityBio (IBRX) Reports 700% Revenue Surge Driven by Rapid ANKTIVA Adoption

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best high volume stocks to invest in now. On February 23, ImmunityBio reported exceptional financial growth for 2025, headlined by a 700% year-over-year increase in net product revenue for its l... Full story

Yahoo Finance • 2 days ago

Sector Update: Health Care Stocks Higher Late Afternoon

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.6% and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 days ago

Why ImmunityBio Stock Is Soaring Again Today

Key Points ImmunityBio's sales grew 700% in 2025, with fourth-quarter revenue rising 20% quarter over quarter. These excellent results extend an incredible run of good news for the up-and-coming biotech stock. While it offers immense pote... Full story

Yahoo Finance • 3 days ago

Stocks making the biggest moves midday: KKR, Blackstone, CrowdStrike, International Paper & more

Check out the companies making the biggest moves midday: Financials – The financials sector of the S & P 500 slid more than 3% in midday trading, the worst performer in the broad market. Alternative asset managers KKR and Blackstone slid r... Full story

Yahoo Finance • 8 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).  Such investors are advised to contact Danielle Peyton at new... Full story

Yahoo Finance • 24 days ago

Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. ImmunityBio, Inc. is among the best biotech stocks. TheFly reported on January 20 that Piper Sandler raised its price target on IBRX to $7 from $5 and maintai... Full story

Yahoo Finance • 2 months ago

ImmunityBio (IBRX) Climbs 7.76% on Europe Expansion

We recently published 10 Big Names Leaving Wall Street in the Dust; 4 at Fresh Highs. ImmunityBio Inc. (NASDAQ:IBRX) is one of the best performers on Friday. ImmunityBio jumped by 7.76 percent on Friday to close at $2.36 apiece after secu... Full story

Yahoo Finance • 3 months ago

ImmunityBio (IBRX) Slashes 9% on Lack of Leads

We recently published 10 Stocks Deep in the Red. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the worst performers on Tuesday. ImmunityBio dropped for a second day on Tuesday, shedding 9.13 percent to close at $2.09 apiece as investors repos... Full story

Yahoo Finance • 3 months ago

ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences

We recently published 10 Stocks Racking Up Big Gains. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the top performers of last week. ImmunityBio rallied for a second day on Friday, soaring 10.80 percent to end at $2.36 apiece, mimicking optim... Full story

Yahoo Finance • 3 months ago

Heights Capital Walks From Archer Aviation: What It Means for Investors

Key Points Sold 2,312,285 shares of Archer Aviation, a net change of approximately $25.09 million Post-trade stake: zero shares, valued at $0 The Archer Aviation position previously accounted for about 6.2% of the fund’s AUM as of the pri... Full story

Yahoo Finance • 3 months ago

Heights Capital Just Ditched Its $12.5 Million AMSC Stake. Here’s What That Might Mean.

Key Points Exited 340,102 shares in American Superconductor, reducing position value by $12.48 million Post-trade stake is zero shares, or $0 value The position was previously 3.3% of the fund's AUM as of the prior quarter These 10 stocks... Full story

Yahoo Finance • 4 months ago

ImmunityBio GAAP EPS of -$0.07 beats by $0.04, revenue of $32.06M beats by $0.18M

* ImmunityBio press release [https://seekingalpha.com/pr/20293555-driven-by-strong-demand-immunitybio-reports-467-percent-year-to-date-unit-growth-and-75] (IBRX [https://seekingalpha.com/symbol/IBRX]): Q3 GAAP EPS of -$0.07 beats by $0.0... Full story

Yahoo Finance • 4 months ago

AstraZeneca PLC (AZN): A Bull Case Theory

We came across a bullish thesis on AstraZeneca PLC on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on AZN. AstraZeneca PLC's share was trading at $85.31 as of October 3rd. AZN’s tra... Full story

Yahoo Finance • 5 months ago

H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 10, H.C. Wainwright reiterated the Buy rating on ImmunityBio, Inc. (NASDAQ:IBRX), keeping the price target at $8. Andr... Full story

Yahoo Finance • 6 months ago

ImmunityBio (IBRX) Reports Initial Study Data Showing 100% Disease Control in Patients With Recurrent Glioblastoma

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best long-term penny stocks to buy right now. On August 26, ImmunityBio, Inc. (NASDAQ:IBRX) announced the early findings of the first five recurrent glioblastoma patients that were treated with... Full story

Yahoo Finance • 6 months ago

CD19 CAR-NK therapy shows complete responses in late-stage lymphoma

CULVER CITY - ImmunityBio (NASDAQ:IBRX), a $2.34 billion market cap biotech company showing remarkable revenue growth of over 4,000% in the last twelve months, reported that its CD19 CAR-NK cell therapy has achieved complete responses in t... Full story

Yahoo Finance • 7 months ago

IBRX Sales Soar 2,540%

Key Points Revenue (GAAP) soared to $26.4 million in Q2 2025, beating GAAP revenue estimates by 14.0%. Net loss per share (GAAP) improved to ($0.10), ahead of expectations. ANKTIVA sales and international launches fueled top-line growth,... Full story

Yahoo Finance • 7 months ago

Immunitybio Inc earnings beat, revenue topped estimates

Investing.com - Immunitybio Inc (NASDAQ: IBRX) reported second quarter EPS of $-0.10, better than the analyst estimate of $-0.11. Revenue for the quarter came in at $26.43M versus the consensus estimate of $21.49M. Immunitybio Inc’s stock... Full story

Yahoo Finance • 7 months ago

VBK's Underlying Holdings Could Mean 12% Gain Potential

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story